tradingkey.logo

Zealand Pharma Announces Positive Results From 28-Week Phase 1B Dapiglutide Trial

ReutersJun 18, 2025 3:36 PM

- Zealand Pharma A/S ZELA.CO:

  • ZEALAND PHARMA ANNOUNCES POSITIVE TOPLINE RESULTS FROM 28-WEEK PHASE 1B TRIAL WITH GLP-1/GLP-2 RECEPTOR DUAL AGONIST DAPIGLUTIDE

  • ZEALAND PHARMA A/S - MEAN BODY WEIGHT REDUCTION OF 11.6% AFTER 28 WEEKS WITH DAPIGLUTIDE

  • ZEALAND PHARMA A/S - DAPIGLUTIDE TREATMENT ASSESSED TO BE SAFE AND WELL-TOLERATED

  • ZEALAND PHARMA A/S - HIGHER DOSES OF DAPIGLUTIDE ASSESSED TO BE SAFE AND WELL-TOLERATED

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI